SWOT Analysis – Hester Biosciences Limited

Strengths One of India's leading animal healthcare companies and the country's second-largest poultry vaccine manufacturer. Diversified portfolio across poultry vaccines, animal vaccines and veterinary health products. Manufacturing footprint in India, Nepal and Tanzania, with presence across 35+ countries. Strong R&D, regulatory and biological manufacturing capabilities. FY25 annual report highlights leadership in PPR vaccines and a strong position in India's goat-pox vaccine segment. Integrated product portfolio provides exposure to poultry, ruminant and pet healthcare. Weaknesses Revenue can be affected by delays in government-led animal immunisation programmes. Relatively smaller scale compared with major global animal-health companies. Vaccine manufacturing requires high regulatory compliance and quality-control expenditure. International manufacturing expansion can increase execution and operating risks. Dependence on poultry and livestock industry conditions. Opportunities Rising demand for animal vaccines and preventive healthcare. Growth in India's poultry, dairy and livestock industries. Expansion in Africa and other emerging international markets. New vaccine development and product launches can strengthen the portfolio. Increasing government focus on livestock disease eradication. Capacity expansion and manufacturing flexibility can support domestic and export growth. Threats Intense competition from domestic and global veterinary healthcare companies. Disease outbreaks can create operational and supply-chain uncertainty. Regulatory approval delays for new vaccines. Raw-material and foreign-exchange volatility. Government tender delays may affect revenue visibility. Product quality or manufacturing compliance issues could significantly affect reputation.